XML 19 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Cash flows from operating activities:      
Net loss $ (36,235,484) $ (39,697,960) $ (39,451,324)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:      
Depreciation and other amortization 132,189 174,275 247,357
Loss on change in fair value of warrant liability 4,738,753 894,785 0
Lease termination 1,225,421 0 0
Stock-based compensation 1,101,031 775,541 1,574,038
Deferred income taxes (benefit)/provision (2,718,029) 20,423 21,103
Write down of inventory, net 536,000 0 0
Non-cash backstop fee 0 (1,764,240) 0
Loss on disposal of assets 0 0 243,707
Non-cash interest expense 4,497,271 566,779 10,052
Interest expense on term loan-paid with restricted cash 10,228,469 1,222,222 0
Changes in assets and liabilities:      
Accounts receivable 1,352,263 522,360 (3,185,098)
Inventory 22,690,715 (13,762,876) 6,597,389
Deferred costs (23,943,057) (19,712,849) (20,075,554)
Prepaid expenses and other current assets (1,065,573) (330,443) 229,266
Other assets (60,084) 80,928 0
Accounts payable, accrued expenses and other current liabilities (1,847,427) (177,342) 1,862,779
Liabilities subject to compromise 0 (160,072,170) (192,067,797)
Deferred revenue 11,412,898 112,225,534 255,176,572
Other liabilities (203,654) (84,228) (73,107)
Net cash (used in) provided by operating activities (8,158,298) (115,590,781) 11,109,383
Cash flows from investing activities:      
Capital expenditures (100,124) (23,927) (108,953)
Return of collateral for surety bond 0 1,212,591 0
Restricted cash 0 0 4,000,000
Net cash (used in) provided by investing activities (100,124) 1,188,664 3,891,047
Cash flows from financing activities:      
Issuance of common stock upon exercise of stock options and warrants 89,498 0 12,200
Net proceeds from equity rights offering-net of offering costs 0 34,596,468 0
Payments for Repurchase of Common Stock (84,000) 0 0
Payment of employee tax obligations for common stock tendered (591,067) (428,009) 0
Debt issuance costs 0 (3,775,546) 0
Repayment of long-term debt 0 0 (2,000,000)
Excess tax benefit from stock-based compensation 0 0 (15,531)
Net cash (used in) provided by financing activities (585,569) 30,392,913 (2,003,331)
Net decrease/increase in cash and cash equivalents (8,843,991) (84,009,204) 12,997,099
Cash and cash equivalents at beginning of period 28,701,824 112,711,028 99,713,929
Cash and cash equivalents at end of period 19,857,833 28,701,824 112,711,028
Supplemental disclosure of cash flows information:      
Portion of Term Loan paid directly to PharmAthene by the Lender in satisfaction of the PharmAthene claim; such liability is part of the Liabilities Subject to Compromise line item 0 46,900,000,000,000 0
Cash interest paid on PharmAthene liability 0 11,668,900,000,000 0
Cash interest paid on Term Loan from restricted cash 10,288,469,000,000 1,222,222,000,000 0
Cash income taxes paid (refund) 325,000,000,000 500,975,000,000 (420,029,000,000)
Fair value of warrant, at issuance date, in connection with loan agreement and recorded as warrant liability $ 0 $ 5,832,624,000,000 $ 0